Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease

NCT01502358 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

FED

Sponsor class

Conditions

Dengue Disease
Dengue Fever

Interventions

BIOLOGICAL: Tetravalent Dengue Vaccine (TVDV)
BIOLOGICAL: Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)
BIOLOGICAL: Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)

Sponsor

U.S. Army Medical Research and Development Command

Collaborators

[object Object]
[object Object]
[object Object]